Evenity (Romosozumab) and Sildenafil: Drug Interaction Guide

Why These Two Drugs Get Prescribed Together

Patients receiving romosozumab for severe osteoporosis are often men over 50 or postmenopausal women, populations where erectile dysfunction and pulmonary arterial hypertension are common comorbidities. Sildenafil use in this age group is widespread: approximately 30 million men in the United States have used a PDE5 inhibitor since the class launched in 1998 [1]. Osteoporosis affects roughly 10.2 million Americans aged 50 and older according to National Health and Nutrition Examination Survey (NHANES) data [2].

The overlap is clinically meaningful. A 68-year-old man with hypogonadism-related bone loss might receive romosozumab 210 mg subcutaneously once monthly while also taking sildenafil 50 mg as needed for erectile dysfunction. His prescriber needs to know whether these agents conflict. The short answer: they do not share metabolic pathways or receptor targets. But the longer clinical picture requires attention to cardiovascular context, which both drug labels flag independently.

Male osteoporosis remains underdiagnosed. The Endocrine Society's 2020 clinical practice guideline estimated that only 10% of men who qualify for osteoporosis treatment actually receive it [3]. When romosozumab is prescribed in this population, concurrent PDE5 inhibitor use should be anticipated and addressed proactively.

Pharmacokinetic Profiles: No Metabolic Overlap

Romosozumab and sildenafil are processed by entirely different biological systems. This separation is the primary reason no pharmacokinetic interaction exists between them.

Romosozumab is a humanized IgG2 monoclonal antibody targeting sclerostin. Like all therapeutic monoclonal antibodies, it undergoes proteolytic degradation into peptide fragments and amino acids through the reticuloendothelial system [4]. It does not interact with cytochrome P450 enzymes, P-glycoprotein transporters, or organic anion transporters. The FDA-approved prescribing information for Evenity explicitly states: "No formal drug interaction studies have been conducted. As a humanized monoclonal antibody, romosozumab is not expected to be metabolized by cytochrome P450 enzymes" [4]. Steady-state concentrations reach approximately 22.2 mcg/mL by month three with the standard 210 mg monthly dose.

Sildenafil follows a completely different route. It is a small molecule absorbed orally and metabolized primarily by hepatic CYP3A4, with a minor contribution from CYP2C9 [5]. Peak plasma concentration occurs at 30 to 120 minutes. The elimination half-life is roughly 3 to 5 hours. Known inhibitors of CYP3A4 (ritonavir, ketoconazole, erythromycin) increase sildenafil exposure significantly; for example, ritonavir 500 mg co-administered with sildenafil 100 mg raised sildenafil AUC by 1,000% in a pharmacokinetic study [5].

Because a monoclonal antibody and a CYP3A4 substrate occupy non-overlapping metabolic lanes, drug-drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not flag a romosozumab-sildenafil interaction. No dose adjustment of either drug is required based on concurrent use alone.

Pharmacodynamic Considerations: Separate Targets, Shared Patient Risk

While the drugs do not interfere with each other's metabolism, the patients who take them often carry cardiovascular risk factors that both labels address.

Romosozumab carries an FDA boxed warning for major adverse cardiovascular events (MACE). The ARCH trial (N=4,093) compared romosozumab to alendronate in postmenopausal women with osteoporosis and found a higher incidence of adjudicated cardiovascular serious adverse events in the romosozumab group: 2.5% versus 1.9% over 12 months of treatment [6]. Myocardial infarction occurred in 16 romosozumab patients versus 5 alendronate patients. Stroke occurred in 16 versus 7. The FDA label consequently states: "Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" [4].

Sildenafil, for its part, is contraindicated with organic nitrates due to severe hypotension risk. The Viagra prescribing information warns of reports of MI, stroke, and sudden cardiac death in temporal association with sildenafil use, though a causal relationship was not established [5]. Sildenafil can lower systolic blood pressure by 8 to 10 mmHg in healthy volunteers taking a single 100 mg dose [5].

The pharmacodynamic concern is not a drug-drug interaction per se. It is the additive cardiovascular risk profile of the patient population receiving both agents. A prescriber should evaluate baseline cardiovascular status before initiating romosozumab in any patient, regardless of sildenafil use.

Dr. Ethel Siris, professor of medicine at Columbia University Irving Medical Center and a principal investigator in the FRAME trial, noted in a 2019 editorial in the Journal of Bone and Mineral Research: "The cardiovascular signal observed with romosozumab mandates careful patient selection, particularly in those with pre-existing cardiovascular disease or multiple risk factors" [7].

The ARCH and FRAME Trials: What the Data Actually Show

The two registration trials for romosozumab provide the foundation for understanding its safety profile in the context of polypharmacy.

The FRAME trial (N=7,180) compared romosozumab 210 mg monthly to placebo for 12 months in postmenopausal women with osteoporosis [8]. At 12 months, romosozumab reduced new vertebral fracture risk by 73% compared to placebo (0.5% vs. 1.8%, P<0.001). Cardiovascular event rates were balanced between groups in FRAME, with adjudicated positively confirmed MACE occurring in 0.5% of both the romosozumab and placebo arms [8].

The ARCH trial told a different story. After 12 months of romosozumab versus alendronate, followed by open-label alendronate in both groups, romosozumab-treated patients had a statistically higher rate of MACE at the 12-month mark: 50 events versus 38 events (hazard ratio 1.31; 95% CI, 0.85 to 2.00) [6]. The difference was driven by cardiac ischemic events and cerebrovascular events.

Neither trial specifically reported on concomitant PDE5 inhibitor use. Trial populations were predominantly postmenopausal women (both FRAME and ARCH), which limits direct extrapolation to male patients taking sildenafil for erectile dysfunction. The BRIDGE study (N=245) evaluated romosozumab in men with osteoporosis and showed similar bone density gains to the female trials, but it was not powered to assess cardiovascular outcomes [9].

Cardiovascular Screening Before Starting Romosozumab

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend cardiovascular risk assessment before prescribing romosozumab [10]. This recommendation applies to all patients. It is not modified by concurrent sildenafil use. But it becomes especially relevant in men using PDE5 inhibitors, who may have underlying coronary artery disease, hypertension, or diabetes.

A pre-treatment cardiovascular workup should include blood pressure measurement, review of cardiac history (prior MI, stroke, TIA, angina), assessment of atherosclerotic cardiovascular disease (ASCVD) 10-year risk score, and evaluation of current cardiac medications. Patients with a history of MI or stroke within the past year should not receive romosozumab per the boxed warning [4].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, stated in a 2020 review published in Therapeutic Advances in Musculoskeletal Disease: "Romosozumab offers substantial fracture risk reduction, but prescribers must weigh this benefit against the cardiovascular signal, especially in patients with established or high-risk cardiovascular disease" [11].

For sildenafil specifically, providers should confirm the patient is not using organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) and is not on alpha-blocker therapy without stable dose titration. These are existing sildenafil contraindications and precautions unrelated to romosozumab [5].

Monitoring During Concurrent Use

No romosozumab-specific lab monitoring is required beyond standard osteoporosis follow-up, but patients on both medications benefit from a structured monitoring plan.

At each monthly romosozumab injection visit, check blood pressure. Romosozumab's 12-month treatment window provides a built-in visit schedule that aligns well with blood pressure surveillance. Serum calcium and 25-hydroxyvitamin D should be checked at baseline and corrected before initiating romosozumab, as hypocalcemia is a known adverse effect occurring in 0.4% of patients in clinical trials [4].

For sildenafil, periodic assessment should include a review of how the patient is responding to the dose, whether new cardiac symptoms have emerged (exertional chest pain, dyspnea, syncope), and whether any new medications have been added that could alter sildenafil's metabolism or hemodynamic effects.

Bone turnover markers (serum P1NP and CTX) can be tracked to confirm romosozumab's anabolic effect. P1NP typically increases by 145% above baseline within one month of romosozumab initiation and returns toward baseline by month 9 [8]. CTX, a bone resorption marker, decreases by roughly 40 to 50% during treatment. These markers are unaffected by sildenafil.

Dose Adjustments and Practical Prescribing

No dose adjustment is necessary for either drug when used concurrently. Romosozumab is administered as two subcutaneous injections of 105 mg each (totaling 210 mg) once monthly by a healthcare professional. This fixed dosing regimen is not modified by any concurrent medication [4].

Sildenafil dosing (25 mg, 50 mg, or 100 mg as needed for erectile dysfunction, or 20 mg three times daily for pulmonary arterial hypertension) follows standard titration based on efficacy and tolerability. CYP3A4 inhibitors warrant dose reduction of sildenafil. Romosozumab is not a CYP3A4 inhibitor. There is no pharmacological basis for altering sildenafil dosing on account of romosozumab.

One practical note: romosozumab injection-site reactions (injection-site pain 5.2%, erythema 2.8%) may cause mild discomfort that coincides with injection day [4]. This is unrelated to sildenafil but worth mentioning so patients do not attribute injection-day symptoms to any other medication they are taking.

Other Romosozumab Drug Interactions to Be Aware Of

Romosozumab's monoclonal antibody structure makes it inherently unlikely to interact with small-molecule drugs. The FDA label does not list any contraindicated drug combinations [4].

Clinically relevant considerations for romosozumab center on sequential osteoporosis therapy rather than drug-drug interactions. After completing 12 months of romosozumab, patients should transition to an antiresorptive agent (alendronate, denosumab, or zoledronic acid) to maintain bone density gains. The ARCH trial demonstrated that patients who transitioned from romosozumab to alendronate achieved a 48% reduction in new vertebral fractures compared to those on alendronate alone over 24 months [6].

Calcium and vitamin D supplementation should be taken with romosozumab. Patients should receive 1 to 000 mg of elemental calcium and at least 600 IU of vitamin D daily unless serum levels indicate otherwise [10]. Calcium absorption may be reduced by proton pump inhibitors (omeprazole, pantoprazole), which is a consideration independent of both romosozumab and sildenafil.

Special Populations: Men with Osteoporosis and ED

The intersection of osteoporosis and erectile dysfunction deserves specific attention because both conditions share pathophysiological links to hypogonadism, aging, chronic disease, and medication effects (glucocorticoids, androgen deprivation therapy).

In the BRIDGE study, romosozumab 210 mg monthly increased lumbar spine BMD by 12.1% at 12 months in men with osteoporosis compared to 1.2% with placebo [9]. The safety profile in men was consistent with the female trials.

Men on androgen deprivation therapy (ADT) for prostate cancer represent a unique subgroup. ADT accelerates bone loss and increases fracture risk. These patients may also experience erectile dysfunction as a direct effect of testosterone suppression. PDE5 inhibitors have limited efficacy in the setting of profound hypogonadism from ADT, but some patients still use them. Romosozumab has not been specifically studied in men on ADT, though denosumab showed fracture reduction in this population in the HALT trial (N=1,468) [12].

For men with both osteoporosis and ED who are not on ADT, the combination of romosozumab and sildenafil is pharmacologically straightforward. The clinical challenge is not the drug-drug interaction. It is ensuring that cardiovascular risk is assessed before romosozumab initiation, as men with erectile dysfunction have a higher baseline prevalence of atherosclerotic cardiovascular disease [13].

Patient Counseling Points

Patients receiving both romosozumab and sildenafil should understand three things clearly. First, the two medications do not interact with each other. They work through completely separate pathways in the body. Second, romosozumab carries a cardiovascular warning, so any new chest pain, sudden severe headache, weakness on one side of the body, or difficulty speaking should prompt immediate medical attention. Third, sildenafil should never be combined with nitrate medications, regardless of whether romosozumab is in the picture.

Patients should inform all prescribers about both medications. This includes the osteoporosis specialist administering romosozumab injections, the primary care physician or urologist prescribing sildenafil, and any emergency department provider.

Report any injection-site reaction that worsens over 48 hours. Notify your provider of any new medication additions, particularly nitrates, alpha-blockers, or strong CYP3A4 inhibitors, which affect sildenafil but not romosozumab.